Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer. A ...

The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Now, the recently published results of an international phase 3 clinical trial led by Australia’s Peter MacCallum Cancer Center (Peter Mac) have shown that using the same kind of treatment ...

Such tumours account for 75% of individuals with endometrial cancer, and present limited treatment alternatives. The expanded ...

A mathematical modeling study conducted in Germany suggests that ovarian cancer incidence could be reduced and health care ...

ASH 2023. Oral 628; Phase 3 TRANSFORM-1 trial Pemmaraju N, et al. ASH 2023 abstract 620. Selinexor in Endometrial Cancer (EC) The Company remains engaged with the FDA regarding the evolving ...

Getty Deaths from uterine cancer are also on the rise, as the study says it’s “one of the few cancers with increasing mortality; from 2013 to 2022 the death rate rose by 1.5% per year.” ...

Death rates for Black people with prostate, stomach, and uterine cancer are twice as high as for white Americans. Cancer cases rising in young people The report does contain some good news ...

Incorporating PROs is particularly important in the context of increasing reliance on surrogate outcomes such as progression-free survival (PFS) in cancer trials. If a new treatment is approved on the ...